Allarity Therapeutics, Inc. (NASDAQ: ALLR), a clinical-stage pharmaceutical company focused on personalized cancer treatments, has announced a significant update to its Board of Directors. Jesper Høiland, a seasoned executive with over three decades of experience in the pharmaceutical industry, has been appointed to the board, effective immediately. This move comes as Joseph Vazzano prepares to step down on June 30, 2025, after two years of service.

Mr. Høiland's appointment is seen as a strategic addition to Allarity's leadership, given his extensive background in global pharmaceutical commercialization and executive roles. His tenure as President and EVP of Novo Nordisk's U.S. operations, along with leadership positions at Radius Health and Ascendis Pharma, underscores his capability to steer companies through critical phases of growth and development. Currently, he also holds board positions at SciBase Holding AB, ALK-Abello A/S, and Flen Health SA.

The transition occurs at a pivotal moment for Allarity, as the company advances its Phase 2 clinical trials for stenoparib, a novel dual PARP and WNT pathway inhibitor. Jerry McLaughlin, Chairman of the Board, expressed enthusiasm about Høiland's joining, highlighting the value of his experience during this period of clinical momentum. McLaughlin also extended gratitude to Vazzano for his contributions, particularly in strengthening the company's governance and operational focus.

Thomas Jensen, CEO of Allarity Therapeutics, remarked on the immediate impact Høiland has had since beginning his consultancy role in October 2024. Jensen emphasized Høiland's strategic advice and his deep understanding of the commercialization process for investigational drugs as key assets for Allarity's future. With Høiland's global network and leadership experience, Allarity is poised to navigate the challenges of bringing personalized cancer treatments to market.

Swedish digital asset manager Virtune has launched what it claims is Europe's most cost-efficient Sui exchange-traded product (ETP) on Euronext Paris, marking another step in the company's expansion across European markets. The Virtune Sui ETP, with the ticker VRTU, provides investors with exposure to the Sui cryptocurrency through a regulated, physically backed investment vehicle. This launch comes as Virtune continues to build its position as one of the leading issuers of regulated crypto ETPs in Europe.

The new ETP features an industry-leading 0.95% annual management fee, making it the most cost-efficient Sui ETP available to European investors. Virtune plans to further expand the product's distribution by listing it on local German exchanges, including gettex and Tradegate, to improve accessibility for German investors. The company has established itself as a trusted provider in the digital asset space, serving over 150,000 investors since its launch just over two years ago.

Security and regulatory compliance remain central to Virtune's approach, with Coinbase serving as the crypto custodian for all of the company's ETPs. The underlying crypto assets are held in cold storage, providing institutional-grade security for investors. This infrastructure supports Virtune's commitment to offering European investors secure, transparent, and regulated access to digital asset markets through traditional investment channels.

Christopher Kock, CEO of Virtune, emphasized the company's mission to make innovative digital assets more accessible to investors. "We are excited to launch the most cost-efficient Sui ETP in Europe, reinforcing our mission to make innovative digital assets more accessible to investors," Kock stated. The launch strengthens Virtune's position as it manages more than $475 million in assets across its product offerings, continuing its growth trajectory in the European digital asset management landscape.